Bulletin
Investor Alert

New York Markets Close in:

Illumina Inc.

NAS: ILMN

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Jan 25, 2022, 3:48 p.m.

/zigman2/quotes/203509482/composite

$

347.80

Change

-17.16 -4.70%

Volume

Volume 828,476

Real time quotes

/zigman2/quotes/203509482/composite

Previous close

$ 364.96

$ 347.80

Change

-17.16 -4.70%

Day low

Day high

$345.88

$358.80

Open

52 week low

52 week high

$341.03

$555.77

Open

Company Description

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Valuation

P/E Current

82.34

P/E Ratio (with extraordinary items)

61.63

P/E Ratio (without extraordinary items)

83.48

Price to Sales Ratio

16.91

Price to Book Ratio

11.51

Price to Cash Flow Ratio

50.19

Enterprise Value to EBITDA

72.33

Enterprise Value to Sales

12.96

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

415,256.00

Income Per Employee

84,103.00

Receivables Turnover

6.11

Total Asset Turnover

0.43

Liquidity

Current Ratio

3.60

Quick Ratio

3.30

Cash Ratio

2.79

Profitability

Gross Margin

68.63

Operating Margin

17.91

Pretax Margin

26.43

Net Margin

20.25

Return on Assets

8.80

Return on Equity

14.10

Return on Total Capital

8.86

Return on Invested Capital

10.51

Capital Structure

Total Debt to Total Equity

40.61

Total Debt to Total Capital

28.88

Total Debt to Total Assets

25.13

Long-Term Debt to Equity

28.63

Long-Term Debt to Total Capital

20.36

Officers and Executives

Name Age Officer Since Title
Mr. Francis A. deSouza 48 2013 President
Mr. Robert P. Ragusa 60 2013 Chief Operations Officer
Mr. Sam A. Samad 49 2017 Chief Financial Officer & Senior Vice President
Dr. Alex Aravanis - 2020 Chief Technology Officer & Senior Vice President
Mr. Steve Phillpott - 2020 Chief Information Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/12/2022 Susan H. Tousi
SVP, Chief Commercial Officer
800   Disposition at $425 per share. 340,000
01/08/2022 Aimee Hoyt
SVP, Chief People Officer
115   Derivative/Non-derivative trans. at $362.28 per share. 41,662
12/28/2021 Susan H. Tousi
SVP, Chief Commercial Officer
100   Disposition at $387.06 per share. 38,706
12/22/2021 Charles E. Dadswell
SVP & General Counsel
322   Disposition at $380.29 per share. 122,453
12/08/2021 Susan H. Tousi
SVP, Chief Commercial Officer
100   Disposition at $375 per share. 37,500
11/22/2021 Charles E. Dadswell
SVP & General Counsel
314   Disposition at $377.86 per share. 118,648
11/12/2021 Alex Aravanis
SVP, Chief Technology Officer
361   Disposition at $386.35 per share. 139,472
11/08/2021 Phillip G. Febbo
SVP Chief Medical Officer
1,000   Disposition at $406.83 per share. 406,830
11/05/2021 Francis A. deSouza
President and CEO; Director
3,604   Derivative/Non-derivative trans. at $408.14 per share. 1,470,936
11/05/2021 Susan H. Tousi
SVP, Chief Commercial Officer
982   Derivative/Non-derivative trans. at $408.14 per share. 400,793
11/05/2021 Sam A. Samad
SVP and CFO
723   Derivative/Non-derivative trans. at $408.14 per share. 295,085
11/05/2021 Kevin Carl Pegels
Chief of Global Operations
574   Derivative/Non-derivative trans. at $408.14 per share. 234,272
11/05/2021 Alex Aravanis
SVP, Chief Technology Officer
191   Derivative/Non-derivative trans. at $408.14 per share. 77,954
11/05/2021 Joydeep Goswami
SVP Corp Business Development
264   Derivative/Non-derivative trans. at $408.14 per share. 107,748
11/05/2021 Charles E. Dadswell
SVP & General Counsel
739   Derivative/Non-derivative trans. at $408.14 per share. 301,615
11/05/2021 Aimee Hoyt
SVP, Chief People Officer
434   Derivative/Non-derivative trans. at $408.14 per share. 177,132
11/05/2021 Phillip G. Febbo
SVP Chief Medical Officer
446   Derivative/Non-derivative trans. at $408.14 per share. 182,030
11/05/2021 Kathy Reeves
SVP, Chief Marketing Officer
97   Derivative/Non-derivative trans. at $408.14 per share. 39,589
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
483   Disposition at $417.62 per share. 201,710
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
200   Disposition at $416.48 per share. 83,296
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
393   Disposition at $413.24 per share. 162,403
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
366   Disposition at $412.15 per share. 150,846
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
645   Disposition at $411.47 per share. 265,398
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
639   Disposition at $410.47 per share. 262,290
11/02/2021 Alex Aravanis
SVP, Chief Technology Officer
200   Disposition at $409.28 per share. 81,856
/news/latest/company/us/ilmn

MarketWatch News on ILMN

  1. PerkinElmer Inc. stock falls Monday, underperforms market

    5:17 p.m. Jan. 24, 2022

    - MarketWatch Automation

  2. Illumina Inc. stock outperforms competitors despite losses on the day

    5:01 p.m. Jan. 24, 2022

    - MarketWatch Automation

  3. PerkinElmer Inc. stock falls Friday, still outperforms market

    5:17 p.m. Jan. 21, 2022

    - MarketWatch Automation

  4. Illumina Inc. stock falls Friday, underperforms market

    5:01 p.m. Jan. 21, 2022

    - MarketWatch Automation

  5. PerkinElmer Inc. stock underperforms Thursday when compared to competitors

    5:17 p.m. Jan. 20, 2022

    - MarketWatch Automation

  6. Illumina Inc. stock falls Thursday, still outperforms market

    5:01 p.m. Jan. 20, 2022

    - MarketWatch Automation

  7. PerkinElmer Inc. stock outperforms competitors on strong trading day

    5:17 p.m. Jan. 19, 2022

    - MarketWatch Automation

  8. Illumina Inc. stock outperforms market on strong trading day

    5:01 p.m. Jan. 19, 2022

    - MarketWatch Automation

  9. PerkinElmer Inc. stock underperforms Tuesday when compared to competitors

    5:17 p.m. Jan. 18, 2022

    - MarketWatch Automation

  10. Illumina Inc. stock falls Tuesday, underperforms market

    5:01 p.m. Jan. 18, 2022

    - MarketWatch Automation

  11. Illumina upgraded to buy from hold at Stifel Nicolaus

    7:02 a.m. Jan. 18, 2022

    - Tomi Kilgore

  12. PerkinElmer Inc. stock falls Friday, underperforms market

    5:17 p.m. Jan. 14, 2022

    - MarketWatch Automation

  13. Illumina Inc. stock rises Friday, outperforms market

    5:01 p.m. Jan. 14, 2022

    - MarketWatch Automation

  14. PerkinElmer Inc. stock outperforms competitors despite losses on the day

    5:17 p.m. Jan. 13, 2022

    - MarketWatch Automation

  15. Illumina Inc. stock outperforms competitors despite losses on the day

    5:01 p.m. Jan. 13, 2022

    - MarketWatch Automation

  16. PerkinElmer Inc. stock rises Wednesday, outperforms market

    5:17 p.m. Jan. 12, 2022

    - MarketWatch Automation

  17. Illumina Inc. stock underperforms Wednesday when compared to competitors

    5:01 p.m. Jan. 12, 2022

    - MarketWatch Automation

  18. PerkinElmer Inc. stock falls Tuesday, underperforms market

    5:17 p.m. Jan. 11, 2022

    - MarketWatch Automation

  19. Illumina Inc. stock outperforms market on strong trading day

    5:01 p.m. Jan. 11, 2022

    - MarketWatch Automation

  20. Loading more headlines...
/news/nonmarketwatch/company/us/ilmn

Other News on ILMN

  1. What's the Outlook for Illumina?

    4:29 p.m. Jan. 23, 2022

    - Motley Fool

  2. Andreas Halvorsen Reinforces Guardant Health Bet

    11:49 a.m. Jan. 19, 2022

    - GuruFocus.com

  3. Wall Street Breakfast: What Moved Markets

    8:08 a.m. Jan. 15, 2022

    - Seeking Alpha

  4. Here's Why You Should Hold on to Illumina (ILMN) for Now

    8:32 a.m. Jan. 14, 2022

    - Zacks.com

  5. Company News for Jan 12, 2022

    9:35 a.m. Jan. 12, 2022

    - Zacks.com

  6. U.S. Stocks Finish Higher as Tech Shares Climb

    5:09 p.m. Jan. 11, 2022

    - Michael Wursthorn

  7. Loading more headlines...

At a Glance

Illumina, Inc.

5200 Illumina Way

San Diego, California 92122

Phone

1 8582024500

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$3.24B

Net Income

$656.00M

Employees

7,800

/news/pressrelease/company/us/ilmn

Press Releases on ILMN

  1. Illumina ILMN Technical Data

    5:54 a.m. Jan. 21, 2022

    - Stock Traders Daily

  2. Promising Developments in Breast Cancer Treatments Ahead in 2022

    10:58 a.m. Jan. 12, 2022

    - PR Newswire - PRF

  3. Promising Developments in Breast Cancer Treatments Ahead in 2022

    10:55 a.m. Jan. 12, 2022

    - Financial News Media

  4. Tuesday's ETF with Unusual Volume: SPYX

    12:35 p.m. Jan. 11, 2022

    - MarketNewsVideo.com

  5. Learn to Evaluate Illumina (ILMN) using the Charts

    11:23 a.m. Jan. 11, 2022

    - Stock Traders Daily

  6. Nasdaq 100 Movers: MRNA, ILMN

    11:23 a.m. Jan. 11, 2022

    - MarketNewsVideo.com

  7. S&P 500 Movers: IBM, ILMN

    11:22 a.m. Jan. 11, 2022

    - MarketNewsVideo.com

  8. Loading more headlines...
Link to MarketWatch's Slice.